A B7-H3 ADC Improves Survival in Relapsed Small-Cell Lung Cancer—but the Numbers Still Matter

원문 링크: WordPress 원문

ENGKOR

A July 10 update from GSK and Hansoh Pharma put an unfamiliar target into the spotlight: B7-H3. Their antibody–drug conjugate risvutatug rezetecan, also called Ris-Rez or HS-20093, met the overall-survival endpoint in a Chinese Phase 3 trial for relapsed small-cell lung cancer.

That is a meaningful result. It is also a topline announcement, not a complete dataset. The most useful way to read it is to keep those two facts together.

What happened in ARTEMIS-008?

ARTEMIS-008 is a randomized, open-label Phase 3 study in China. The ClinicalTrials.gov record, NCT06498479, describes an estimated 460 adults whose small-cell lung cancer returned after platinum-based first-line chemotherapy. Participants were assigned to either risvutatug rezetecan at 8 mg/kg intravenously every three weeks or topotecan.

Overall survival was the primary endpoint. According to GSK’s July 10 stock-exchange announcement and SEC filing, Ris-Rez produced a statistically significant and clinically meaningful improvement in overall survival compared with topotecan. GSK also reported a consistent benefit in progression-free survival and said that no new safety signals were identified.

Hansoh plans to use the result for a regulatory submission in China. The announcement does not mean that the drug is already approved in China, the United States, or another market.

The result is positive, but the numbers are not public yet

The headline tells us that the trial crossed its prespecified survival threshold. It does not tell us how large or durable that benefit was.

Publicly reported Not yet publicly reported

The overall-survival endpoint was met Median overall survival in each group

The comparison favored Ris-Rez over topotecan Hazard ratio, confidence interval, and exact p value

Progression-free survival also favored Ris-Rez Median PFS and its effect estimate

No new safety signal was reported by GSK Full adverse-event rates, dose modifications, and discontinuations

The study was conducted in a Chinese population Prespecified subgroup results and data maturity

This distinction matters. “Statistically significant” answers whether the observed difference is unlikely to be explained by chance under the trial’s assumptions. It does not, by itself, show the absolute number of extra months gained, how many patients experienced serious toxicity, or whether the result applies equally to every subgroup.

Until the full presentation or paper is available, the correct conclusion is narrow: ARTEMIS-008 met its survival endpoint, while the magnitude and complete safety profile remain to be evaluated.

Conceptual illustration of B7-H3 binding, cellular uptake, and topoisomerase-inhibitor payload release; not a depiction of clinical treatment success

How does a B7-H3 antibody–drug conjugate work?

An antibody–drug conjugate can be pictured as three connected parts.

• Antibody: Ris-Rez uses an antibody designed to recognize B7-H3, also called CD276, on the surface of tumor cells.

• Linker: A chemical linker carries the drug payload while the conjugate travels through the body.

• Payload: After the conjugate binds and is taken into a cell, it delivers a topoisomerase-inhibitor payload intended to damage DNA and kill the cell.

B7-H3 is found at high levels in many small-cell lung cancers, which makes it an attractive delivery address. But target expression alone does not guarantee benefit. An ADC still has to reach the tumor, release enough active payload, and maintain a tolerable safety profile.

That last point is especially important because the payload is a potent cytotoxic drug. The antibody may concentrate exposure toward tumor cells, but it does not make systemic toxicity disappear.

What the earlier Phase 1 study adds—and what it cannot answer

The 2026 ARTEMIS-001 publication in Cancer Cell provides useful background, but it is a different study from ARTEMIS-008.

ARTEMIS-001 enrolled 306 patients with previously treated advanced solid tumors. Among response-evaluable patients with extensive-stage small-cell lung cancer, the confirmed objective response rate was 52.3% in a group of 65 patients. The investigators selected 8 mg/kg for Phase 3 development.

The same publication also shows why safety cannot be reduced to the phrase “no new signals.” Among 236 lung-cancer patients treated at 8 or 10 mg/kg, grade 3 or higher decreases in neutrophils and white blood cells, as well as anemia, were common and more frequent at the higher dose. Treatment-related interstitial lung disease occurred in 3.4%, while adverse events leading to death occurred in 3.8%.

These figures belong to the earlier, nonrandomized Phase 1 study. They should not be copied into the Phase 3 safety column. Their role is to identify issues to look for when the complete ARTEMIS-008 results are released.

Why a China-only Phase 3 result is not the same as a global approval package

Hansoh retains rights in mainland China, Hong Kong, Macau, and Taiwan. GSK holds development and commercialization rights elsewhere.

The positive Chinese study strengthens the biological and clinical case for Ris-Rez, but GSK’s global program remains separate. The global Phase 3 study NCT07099898 is recruiting an estimated 420 participants across multiple countries and also compares Ris-Rez with topotecan in relapsed small-cell lung cancer. Its primary endpoint is overall survival.

The U.S. FDA has granted Ris-Rez Breakthrough Therapy and Orphan Drug designations in small-cell lung cancer. These designations can support development or review, but they are not marketing approval and do not guarantee that a future application will be accepted or approved.

What to watch next

The next useful evidence will not be another adjective such as “positive” or “promising.” It will be the actual dataset:

• median overall survival and the hazard ratio;

• progression-free survival, response duration, and subgroup consistency;

• grade 3 or higher toxicities, interstitial lung disease, treatment discontinuations, and deaths;

• how mature the survival data are;

• whether Chinese regulators accept the submission; and

• whether the separate global Phase 3 trial reproduces the benefit.

For now, ARTEMIS-008 is an important milestone for both Ris-Rez and the B7-H3 ADC field. It is the first publicly reported positive Phase 3 overall-survival result for a B7-H3-targeted ADC in any tumor type. The result deserves attention—but not a blank check.

Sources

• GSK stock-exchange announcement, 10 July 2026

• GSK Form 6-K filed with the U.S. SEC

• ARTEMIS-008 registry: NCT06498479

• ARTEMIS-001 Phase 1 publication: PMID 41791381

• Global Phase 3 registry: NCT07099898

• GSK–Hansoh licensing agreement

This article is for scientific and educational information only. It is not medical advice or investment advice. Risvutatug rezetecan remains an investigational medicine, and treatment decisions should be discussed with qualified healthcare professionals.